Skip to main content

Artificial intelligence and informatics in veterinary oncology

Veterinary Oncology is calling for submissions to our Collection on "Artificial intelligence and informatics in veterinary oncology." This collection aims to advance the field with cutting-edge research that harnesses these rapidly-evolving technologies to improve cancer care for animals.

Waivers available

For articles submitted in 2024 and 2025, Veterinary Oncology has waivers available to offer that can be requested upon submission and allocated on acceptance. Once the standard peer review process has been completed and the Editors have made a decision to accept the article, authors without funding available won’t need to pay an APC. Enquire here for more information.

Veterinary Oncology is accepting submissions and will publish its first articles soon.

Join us as an Editorial Board Member

We are recruiting Editorial Board Members with expertise across all areas of our scope. Reach out and apply.

Aims and scope

Veterinary Oncology will aim to cover all aspects of cancer research and clinical management in veterinary medicine. It will focus on the diagnosis, treatment, and prevention of cancer in various animal species, including but not limited to dogs, cats, horses, food animals, wildlife and exotic/zoo animals. The journal will welcome original research articles, reviews, case reports, and clinical studies that contribute to advancing knowledge in veterinary oncology. Topics of interest include cancer biology, tumor pathogenesis, novel therapies, diagnostic techniques and palliative care. We expect high welfare and ethical standards to be observed in all submitted work and that all relevant legislation and professional guidelines should be followed.

Meet the Editors-in-Chief

Our new Editors-in-Chief, Dr. Amy LeBlanc and Prof. David Killick, answer 5 questions on their research backgrounds, career highlights, and their plans for Veterinary Oncology.

To read the Q&A, visit the Springer Nature Cancer Community page.


New Content ItemDr. Amy LeBlanc, BS, DVM, DipACVIM (Onc), National Cancer Institute, NIH, USA

Dr. Amy LeBlanc is a board-certified veterinary oncologist, Senior Scientist and Director of the CCR Comparative Oncology Program at the National Cancer Institute, NIH. In this position, she directly oversees and manages the operations of the Comparative Oncology Trials Consortium (COTC), which designs and executes clinical trials of new cancer therapies in tumor-bearing pet dogs. Dr. LeBlanc is a graduate of Michigan State University, holding both BS and DVM degrees.

New Content Item

Prof. David Killick, BVetMed PgDip-AP, PhD, CertSAM DipECVIM-CA (Onc), FHEA, FRCVS, RCVS Specialist, and EBVS® European Specialist in Veterinary Oncology (Small Animals), University of Liverpool, UK

David is Professor of Small Animal Oncology at the University of Liverpool, UK and current Chair of the ECVIM Oncology Specialty Group. He is interested in all aspects of clinical oncology especially treatment of canine melanoma and lymphoma in the cat and dog. David’s current research interests include tumour registries, medication safety and cancer immunology. He received his PhD and BVetMed from the Royal Veterinary College, University of London.